This is the authors' abstract. We don't add key points for this paper.
Formulation of Ranolazine in the form of extended-release tablet in 500 mg dosage form was performed using Eudragit L100-55 as a retarding agent. Drug-release profiles were investigated in comparison with the reference Ranexa extended-release 500 mg tablet. F2 and f1 were calculated as 64.16 and 8.53, respectively. According to Peppas equation, the release of drug is controlled by diffusion (n=0.5). The tablets were put into accelerated stability condition (40⁰C, 75% humidity) for 3 and 6 months. The dissolution release profiles and other physical and chemical characteristics of the tablets confirmed the robustness and stability of formulation in this condition.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Farzad Khajavi (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: